![]() |
Name |
(3E,5Z,8S,10E)-8-hydroxytrideca-3,5,10,12-tetraen-2-one
|
Molecular Formula | C13H18O2 | |
IUPAC Name* |
(3E,5Z,8S,10E)-8-hydroxytrideca-3,5,10,12-tetraen-2-one
|
|
SMILES |
CC(=O)/C=C/C=C\C[C@H](C/C=C/C=C)O
|
|
InChI |
InChI=1S/C13H18O2/c1-3-4-6-10-13(15)11-8-5-7-9-12(2)14/h3-9,13,15H,1,10-11H2,2H3/b6-4+,8-5-,9-7+/t13-/m0/s1
|
|
InChIKey |
WLKGLBGVBUEPDA-IGGQVBTJSA-N
|
|
Synonyms |
(3E,5Z,8S,10E)-8-hydroxytrideca-3,5,10,12-tetraen-2-one
|
|
CAS | NA | |
PubChem CID | 156582495 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 206.28 | ALogp: | 2.4 |
HBD: | 1 | HBA: | 2 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 37.3 | Aromatic Rings: | 0 |
Heavy Atoms: | 15 | QED Weighted: | 0.512 |
Caco-2 Permeability: | -4.674 | MDCK Permeability: | 0.00002590 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.28 |
Human Intestinal Absorption (HIA): | 0.011 | 20% Bioavailability (F20%): | 0.012 |
30% Bioavailability (F30%): | 0.007 |
Blood-Brain-Barrier Penetration (BBB): | 0.439 | Plasma Protein Binding (PPB): | 48.29% |
Volume Distribution (VD): | 0.991 | Fu: | 54.57% |
CYP1A2-inhibitor: | 0.019 | CYP1A2-substrate: | 0.119 |
CYP2C19-inhibitor: | 0.027 | CYP2C19-substrate: | 0.599 |
CYP2C9-inhibitor: | 0.026 | CYP2C9-substrate: | 0.915 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.915 |
CYP3A4-inhibitor: | 0.018 | CYP3A4-substrate: | 0.169 |
Clearance (CL): | 6.558 | Half-life (T1/2): | 0.84 |
hERG Blockers: | 0.029 | Human Hepatotoxicity (H-HT): | 0.772 |
Drug-inuced Liver Injury (DILI): | 0.051 | AMES Toxicity: | 0.366 |
Rat Oral Acute Toxicity: | 0.858 | Maximum Recommended Daily Dose: | 0.974 |
Skin Sensitization: | 0.967 | Carcinogencity: | 0.89 |
Eye Corrosion: | 0.691 | Eye Irritation: | 0.976 |
Respiratory Toxicity: | 0.963 |